Botox for Migraines: Effective Across Racial Groups

Research Summary

A recent study published in Headache explored the effectiveness and safety of onabotulinumtoxinA as a preventive treatment for chronic migraine across diverse racial groups. The COMPEL trial included 716 participants: 582 White, 89 Asian, and 41 Black/African American. The study found that all subgroups experienced significant reductions in monthly headache days (MHDs) by week 108, with 60%-73% achieving a ≥50% reduction in MHDs. Improvements were also noted in headache impact, migraine disability, and quality of life measures. The safety profile was consistent with prior findings, indicating that onabotulinumtoxinA is a safe and effective treatment across these racial subgroups.

Study Details

📄 Title: OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trial.

👥 Research Team: Blumenfeld AM et al.

📚 Published In: Headache

📅 Publication Date: 2025 Dec 15

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.